Mesothelioma-binding antibodies: Thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma

Histopathology

Volumn 29, Issue 3, 1996, Pages 209-215

  Attanoos, R L ^a,b   Goddard, H ^b   Gibbs, A R ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Adenocarcinoma; HBME 1; Mesothelioma; OV 632; Thrombomodulin

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOMODULIN;

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIOMA; PRIORITY JOURNAL;

EID: 0029784904     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.1996.tb01393.x     Document Type: Article

References (27)

1. Skov BG, Lauritzen AF, Hirsch F, Nielsen HW. The histopathological diagnosis of malignant mesothelioma v pulmonary adenocarcinoma: reproducibility of the histological diagnosis. Histopathology 1994: 24; 553-557.
2. Ordonez NG. The Immunohistochemical Diagnosis of Mesothelioma. Am. J. Surg. Pathol. 1989: 13; 276-291.
3. Warhol MJ, Hickey WF, Corson JM. Malignant mesotheliomas: ultrastructural distinction from adenocarcinomas. Am. J. Surg. Pathol. 1982: 6; 307-314.
4. Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am. J. Surg. Pathol. 1985: 9; 360-365.
5. Jasani B, Edwards RE, Thomas ND and Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Vrichows Arch. (Pathol Anat.) 1985: 406; 441-448.
6. Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembronic antigen in the diagnosis of malignant mesothelioma. Am. J. Surg. Pathol. 1984: 8; 277-279.
7. Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: an immunohistologic analysis demonstrating the value of Leu M1 antigen. Am. J. Pathol. 1986: 123; 212-219.
8. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembronic antigen, keratin proteins, epithelial membrane antigen and milk fat globule-derived antigen. Hum. Pathol. 1987: 18; 67-74.
9. Gibbs AR, Harach R, Wagner JC, Jasani B. Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma. Thorax 1985: 40; 91-95.
10. Szpak CA, Johnston WW, Roggli V et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am. J. Pathol. 1986: 28; 17-21.
11. Sheibani K, Shin SS, Kezirian J, Weiss LM, Ber EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma and adenocarcinoma. Am. J. Surg. Pathol. 1991: 15; 779-784.
12. Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesothelioms of the pleura. Histopathology. 1984: 8; 793-803.
13. Rasmussen OO, Larsen KE. S100 protein in malignant mesotheliomas. Acta Pathol. Microbiol. Immunol. Scand [A]. 1985: 93; 199-201.
14. Anderson TM, Holmes EC, Kosaka CJ et al. Monoclonal antibodies to human malignant mesothelioma. J. Clin. Immunol. 1987: 7; 254-261.
15. Hsu SM, Hsu PL, Zhao X et al. Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential. Cancer Res. 1988: 48; 5228-5236.
16. O'Hara CJ, Corson JM, Pinkus GS et al. A monoclonal antibody that distinguishes epithelial-type mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am. J. Pathol. 1990: 136; 421-428.
17. Donna A, Betta PG, Bellingeri D, Marchesini A. New marker for mesothelioma: an immunoperoxidase study. J. Clin. Pathol. 1986: 39; 961-968.
18. World Health Organisation. Histological Typing of Lung Tumours. 2nd ed. Geneva: WHO, 1981; 21-32.
19. Maruyama I, Bell C, Majerus P. Thrombomodulin is found on endothelium of arteries, veins, capillaries,and lymphatics, and on syncytiotrophoblasts of human placenta. J. Cell Biol. 1985: 101; 363-371.
20. Appleton MAC, Attanoos RL, Gibbis AR. Thrombomodulin as a marker of lymphatic endothelium. J. Pathol. 1995: 176; 26A.
21. Collins C, Ordonez NG, Schaefer R et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992: 141; 827-833.
22. Attanoos RL, Appleton MAC, Goddard H, Gibbs AR. Thrombomodulin expression in malignant peritoneal mesothelioma and serous papillary adenocarcinoma of the ovary. J. Pathol. 1995: 176; 49A.
23. Attanoos RL, Goddard H, Thomas ND, Jasani B, Gibbs AR. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: The diagnostic utility of LEU-M1, BER-EP4. Tamm-Horsfall protein and thrombomodulin. Histopathology 1995: 27; 361-366.
24. Fleuren GJ, Coerkamp EG, Nap M, Van den Broek LJCM. Warnaar SO. Immunohistological characterization of a monoclonal antibody (OV 632) against epithelial ovarian carcinomas. Virchows Arch. (Pathol. Anat.) 1987:410; 481-486.
25. Delahaye M, Hoogsteden HC, van der Kwast TH. Immunocytochemistry of malignant mesothelioma: OV 632 as a marker of malignant mesothelioma. J. Pathol. 1991: 165; 137-143.
26. Edwards C, Oates J. OV 632 and MOC 31 in diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material. J. Clin. Pathol. 1995: 48; 626-30.
27. Sheibani K, Esteban J, Bailey A, Battifora H, Weiss L. Immunopathologic and Molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum. Pathol. 1992: 23; 107-116.